Maze Therapeutics’ (MAZE) “Outperform” Rating Reiterated at Wedbush

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “outperform” rating reiterated by research analysts at Wedbush in a note issued to investors on Wednesday, September 23rd, Benzinga reports. They currently have a $48.00 price objective on the stock. Wedbush’s price target indicates a potential upside of 75.53% from the stock’s current price.

A number of other research firms also recently weighed in on MAZE. BTIG Research restated a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Tuesday, September 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a report on Monday, September 21st. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Citigroup began coverage on shares of Maze Therapeutics in a report on Wednesday, September 23rd. They issued a “buy” rating and a $50.00 price target for the company. Finally, TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $63.40.

Maze Therapeutics Stock Performance

NASDAQ MAZE traded up $0.33 during trading hours on Wednesday, hitting $27.35. 26,310 shares of the stock were exchanged, compared to its average volume of 663,524. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -10.89 and a beta of 2.17. Maze Therapeutics has a 12-month low of $21.95 and a 12-month high of $53.65. The stock has a 50-day moving average of $27.04 and a 200 day moving average of $28.57.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). As a group, equities research analysts forecast that Maze Therapeutics will post -2.72 earnings per share for the current year.

Insider Activity

In related news, insider Courtney Phillips sold 2,012 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $52,332.12. Following the completion of the sale, the insider directly owned 7,007 shares of the company’s stock, valued at approximately $182,252.07. This trade represents a 22.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Harold Bernstein sold 9,705 shares of Maze Therapeutics stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $26.22, for a total value of $254,465.10. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 134,849 shares of company stock worth $3,582,240 over the last three months. Insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Frazier Life Sciences Management L.P. boosted its position in shares of Maze Therapeutics by 10.2% during the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after buying an additional 465,641 shares during the period. TRV GP IV LLC bought a new stake in shares of Maze Therapeutics during the second quarter valued at about $133,502,907. ARCH Venture Management LLC bought a new position in Maze Therapeutics in the 2nd quarter valued at about $122,983,582. BlackRock Inc. bought a new position in shares of Maze Therapeutics in the second quarter valued at approximately $104,525,000. Finally, Jupiter Topco LLC bought a new position in Maze Therapeutics during the 2nd quarter valued at $101,764,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.